The Week in Review: November 10 – November 17, 2017

Friday, November 17, 2017 News Recap: AASLD 2017 HCV Clinical Guidelines and Patient Management highlights from The Liver Meeting 2017. Thanks to the Canadian Society for International Health we are able to share this excellent presentation, by Dr. Curtis Cooper, on highlights from AASLD 2017. Liver Cancer Global Perspectives on Hepatocellular Carcinoma.  Be sure to check out this excellent article! A panel of international oncology experts rece...

HCV Clinical Guidelines and Patient Management highlights from The Liver Meeting 2017

Please find the attached HCV Clinical Guidelines and Patient Management highlights from The Liver Meeting® hosted by The American Association for the Study of Liver Diseases in October 2017, in Washington D.C. The presentation was prepared by Dr. Curtis Cooper, Director of The Ottawa Hospital and Regional Viral Hepatitis Program, please contact Dr. Cooper if you have any questions. Click on Image to view PDF Ecaterina Perean Damian, MPH,

Global Perspectives On Hepatocellular Carcinoma

A panel of international oncology experts recently met to exchange thoughts on developments in the field of hepatocellular carcinoma (HCC), the most common form of liver cancer. They discussed screening and staging issues, treatment of advanced HCC and results of recent clinical trials. Treating hepatocellular carcinoma (HCC), the most common form of liver cancer, is exceptionally challenging today. Even as new therapies are on the horizon that show some

Liver test to aid paracetamol overdose treatment

People who overdose on paracetamol (acetaminophen) could be helped by a blood test that shows immediately if they are going to suffer liver damage. Researchers in Edinburgh and Liverpool said the test would help doctors identify which patients arriving in hospital need more intensive treatment. The blood test detects levels of specific molecules in blood associated with liver damage. The three different molecules are called miR-122, HMGB1 and FL-K18

Nivolumab improves outcomes in liver cancer study

The median overall survival was 15.0 and 15.6 months in the two sorafenib-experienced groups. In comparison, people who switched from sorafenib to a recently approved similar drug, regorafenib (Stivarga), had a median survival of about 11 months. The median survival for the sorafenib-naive group could not be determined because a majority of patients were still alive, but this was projected to be 28.6 months. Nivolumab (Opdivo), a PD-1 checkpoint inhibitor

DAAs produce cure rates in HCV/HIV co-infection similar to monoinfection

Using direct-acting antiviral therapies demonstrated similarly high rates of sustained virologic response for hepatitis C virus infection in patients with and without HIV infection as compared with rates for HCV mono-infected patients, according to findings published in Hepatology. “Because of low [sustained virologic response] rates associated with interferon-based therapies, the accelerated progression of HCV related liver disease, and barriers to recei

The Hidden Disease of the Middle-Aged

Liver disease is on the rise among middle-aged Americans, but many don’t know they have it—or that they could develop it. The liver performs critical jobs, including cleaning toxins from the blood, storing energy and nutrients, digesting fats and processing medications, alcohol and food. But a host of ills and abuses can wreak havoc on the liver, from heavy drinking and infection with hepatitis B or C to a scourge known as fatty-liver disease linked to di

U.S.: Dynavax Announces FDA Approval of HEPLISAV-B™ for Prevention of Hepatitis B in Adults

First and Only Two-Dose Vaccine in United States for Prevention of Hepatitis B in Adults. First New Hepatitis B Vaccine in United States in More than 25 Years.  BERKELEY, CA--(Marketwired - November 09, 2017) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration (FDA) has approved HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for prevention of infection caused by all known subtypes of hep

How chronic inflammation tips the balance of immune cells to promote liver cancer

Study explains success of some types of cancer immunotherapy, provides new targets for the development of additional immunotherapies Chronic inflammation is known to drive many cancers, especially liver cancer. Researchers have long thought that's because inflammation directly affects cancer cells, stimulating their division and protecting them from cell death. But University of California San Diego School of Medicine researchers have now found that chron

The Week in Review: November 4 – November 10, 2017

Friday, November 10, 2017 News Recap: Canada: Updated List of Physicians in British Columbia Currently Treating Hepatitis B and/or Hepatitis C. HepCBC has updated its list of Doctors in BC who treat HCV and HBV. Direct-Acting Antiviral Therapy Outcomes in Canadian Chronic Hepatitis C Telemedicine Patients. Many of the 300,000 HCV-infected Canadians live in under-served and remote areas without access to HCV healthcare specialists. Telemedicine (T...